76 results about "Pigmented Epithelium" patented technology

The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.

The present invention is directed to methods for altering the fate of a cell, tissue or organ type by altering Notch pathway function in the cell. The invention is further directed to methods for altering the fate of a cell, tissue or organ type by simultaneously changing the activation state of the Notch pathway and one or more cell fate control gene pathways. The invention can be utilized for cells of any differentiation state. The resulting cells may be expanded and used in cell replacement therapy to repopulate lost cell populations and help in the regeneration of diseased and / or injured tissues. The resulting cell populations can also be made recombinant and used for gene therapy or as tissue / organ models for research. The invention is directed to methods for of treating macular degeneration comprising altering Notch pathway function in retinal pigment epithelium cells or retinal neuroepithelium or both tissues. The present invention is also directed to kits utilizing the methods of the invention to generate cells, tissues or organs of altered fates. The invention also provides methods for screening for agonists or antagonists of Notch or cell fate control gene pathway functions.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

The present invention relates to compositions and methods, in particular to methods based on systemic administration of scAAV, for delivering genes to cells of the retina of mammals, and in particular to photoreceptor cells, ganglion cells, glial cells, inner nuclear layer cells or cells of the retinal pigmented epithelium.

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca<2+>-channels or on the [<3>H]-ryanodine receptors of the retinal pigment epithelium.

The present disclosure relates to compositions and methods for treating retinal damage and / or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and / or a nucleoside or nucleotide reverse transcriptase inhibitor.

The invention relates to a retina pigment epithelial cell culture medium and an application thereof. The retina pigment epithelial cell culture medium comprises a first RPE (Retinal Pigment Epithelium) cell culture medium and a second RPE cell culture medium, wherein the first RPE cell culture medium and the second RPE cell culture medium are respectively used in 1.5 weeks, a RPE monolayer cell needed for cell replacement therapy can be quickly cultured; and the cultured RPE is polygonal, embedded and polarly-arranged monolayer cell and has the normal biological functions. Compared with the prior art, the RPE monolayer cell needed for cell replacement therapy can be quickly cultured in 1.5 weeks under the precondition that the conventional laboratory consumables are used; and the retina pigment epithelial cell culture medium is relatively low in cost and high in proliferation speed.

The invention provides an iPSC residue detection method using ESRG gene as a universal marker gene. According to the iPSC residue detection method using the ESRG gene as the universal marker gene, thenumber of the ESRG genes in a sample is quantitatively detected through a qPCR detection method, so that iPSC residues in the sample are detected. According to the method, an ESRG gene segment is adopted as the universal marker gene, a series of cells including endothelial progenitor cells, neural stem cells, retinal pigment epitheliums, hepatocytes, natural killer cells, myocardial cells, isletbodies and the like can be detected, and the marker gene does not need to be replaced; and meanwhile, detection can be carried out in a short time, and the detection efficiency is greatly improved. According to the method, during detection, only mRNA extraction, reverse transcription and qPCR reagents are needed, the cost is low, and the accuracy is high.

The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.

The invention provides a measuring device for quantatively assessing photic injury of retinal pigment epithelial cells due to a light source and a quantitative assessment method based on the measuring device.The method enables quick, efficient and accurate assessment on quantitative indexes of retinal photic injury.The measuring device can provide stable testing environment and testing conditions, and it is possible to accurately and effectively assess photic injury degree of retinal pigment epithelial cells due to the light source.The problem that results of evaluation by the use of an existing retinal pigment epithelial cell line, such as presence or absence of photic injury, have the major problems with repeatability and accuracy is effectively solved, so that data support is provided for the research and development and scientific research of related lighting products.

The invention provides an inhibitor for autophagy and apoptosis of retinal pigment epithelial cells RPE and application of the inhibitor, and relates to the technical field of biological medicines. The invention relates to an inhibitor for autophagy and apoptosis of retinal pigment epithelial cells RPE. The inhibitor comprises an antagonist Met of a tumor necrosis factor superfamily receptor FAS.It is verified that the tumor necrosis factor superfamily receptor FAS can serve as a receptor of GMFB to activate downstream autophagy and apoptosis pathways, the antagonist Met of the tumor necrosisfactor superfamily receptor FAS can inhibit activation of the FAS and downstream related pathways of the FAS, cell apoptosis and autophagy reactions are reduced, and therefore the morbidity process of diabetic retinopathy is delayed. The inhibitor can be used for preparing medicines for delaying and / or treating diabetic retinopathy in the early stage of disease.

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

The present invention relates to compositions and methods, in particular to methods based on systemic administration of scAAV, for delivering genes to cells of the retina of mammals, and in particular to photoreceptor cells, ganglion cells, glial cells, inner nuclear layer cells or cells of the retinal pigmented epithelium.

A device for fusing two or more tissues is disclosed. The device comprises a hand held probe comprising a fluid receiving opening, a channel and an outlet in fluid communication whereby fluid passes through the channel and exits the outlet where it is directed to at least one of the two or more tissues and / or a space in-between. A disruptive emitter comprised on the probe which emits a force sufficient to fuse the two or more tissues. The device finds particular application to treatment of a detached retina by fusing the retina and the retinal pigmented epithelium. A method of fusing two or more tissues including a retina and underlying retinal pigmented epithelium is also disclosed.

The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule.In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.

The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and / or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

The invention provides a solution to the clinical problem of retinal pigment epithelium (RPE) degeneration or geographic atrophy (GA) associated with AMD. PPARΥ selective agonists, e.g., troglitazone and analogs thereof are used to reduce or inhibit RPE degeneration, GA, and / or the progression of dry AMD.

Automated and objective methods for quantifying a retinal characteristic include segmenting an optical coherence tomography image into a plurality of layered retinal regions, and quantifying the retinal characteristic for each region as normalized to a range defined by the characteristic value in the vitreous region and in the retinal pigment epithelium region. Such methods are useful for detecting occult ocular pathology, diagnosing ocular pathology, reducing age-bias in OCT image analysis, and monitoring efficacy ocular / retinal disease therapies.

The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.

This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one or more compounds which modulate Nox4, formation of radical oxygen species, serine protease, a dopamine receptor, NF-kB, mTOR, AMPK, RPE epithelial to mesenchymal transition, RPE dedifferentiation, or one or more Rho GTPases; and kits for administration of the methods.

A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGFβ superfamily.

The invention relates to the technical field of biology, and particularly discloses application of a small molecule compound composition in preparation of a medicine for preventing and treating retinal injury diseases. The small molecule compound composition effectively antagonizes cell death and dysfunction caused by oxidative stress on retinal pigment epithelial cells, and can effectively protect the retinal pigment epithelial cells so as to protect the structural integrity and normal function of the whole retinal layer cells; the compound can be used for preventing and potentially treating retinal injury caused by oxidative stress, and is particularly favorable for preventing and / or treating age-related maculopathy and other retinal injury diseases. Besides, experiments prove that the small molecule compound composition has no obvious pharmacological toxicity and can effectively control occurrence and development of retinal injury diseases, and a new theoretical support is provided for development of unknown biological activity and future clinical treatment effects of the small molecule compound composition.

The present invention is directed to compositions for treating oxidative-stress related-damage of retinal pigment epithelium (RPE) cells by contacting orbital fat-derived mesenchymal cell with the damaged RPE cells.

A device for fusing two or more tissues is disclosed. The device comprises a hand held probe comprising a fluid receiving opening, a channel and an outlet in fluid communication whereby fluid passes through the channel and exits the outlet where it is directed to at least one of the two or more tissues and / or a space in-between. A disruptive emitter comprised on the probe which emits a force sufficient to fuse the two or more tissues. The device finds particular application to treatment of a detached retina by fusing the retina and the retinal pigmented epithelium. A method of fusing two or more tissues including a retina and underlying retinal pigmented epithelium is also disclosed.

A multi-spot ophthalmic laser device that produces spatially distributed laser spots with the spatial distribution of the laser spots defined by a spot diameter to space ratio in the range 1:2 to 1:20. The multi-spot ophthalmic laser device comprises: a laser module producing a laser pulse or sequence of laser pulses each having: a pulse duration in the range of 10 ps to 20 μs; a wavelength in the range 500 nm to 900 nm; and a pulse energy in the range 10 μJ to 10 mJ per pulse; and an optical beam profiling module that modifies an output beam profile of each pulse of the laser module to deliver multiple spatially distributed laser spots of defined size and energy. The multi-spot ophthalmic laser device is used in a method of improving the function of the retina of a human eye by irradiation through the cornea of the eye to the retinal pigmented epithelium by a treatment laser having a beam profile with spatially distributed energy peaks.

The invention relates to a preparation method of retinal pigment epithelial cells. The preparation method comprises the following steps: providing pluripotent stem cells; culturing the pluripotent stem cells to form embryoid bodies; using a culture medium containing Dorsomorphin and SB431542 for carrying out suspension culture on the embryoid body; after the suspension culture, a culture medium containing nicotine is used for carrying out adherent culture on the embryoid body for more than three weeks, Activin A is added into the culture medium for culture in the second week to the third week of the adherent culture, and the retinal pigment epithelial cells and the retinal pigment epithelial cell precursors are obtained. According to the preparation method disclosed by the invention, the culture medium needs fewer added components and is free of animal-derived components, the quantity of harvested cells is large, the induction efficiency is high, and a quality guarantee can be provided for the production of the retinal pigment epithelial cells.

The invention relates to a retinal pigment epithelial cell induction medium and application thereof. The induction medium is a Neurobasic medium containing the following components: a B27 supplement, 1 mM to 5 mM of L-glutamine, 0.5 mM to 3 mM of sodium pyruvate, 0.05 mM to 0.15 mM of beta-mercaptoethanol, 30 mM to 120 [mu] M of L-ascorbic acid, 0.5 mM to 3 mM of cAMP, 30 nM to 120 nM of a BMP inhibitor, 5 [mu] M to 20 [mu] M of a GSK-3beta inhibitor, 5 [mu] M to 25 [mu] M of an ALK inhibitor and 15 ng / ml to 60 ng / ml of SHH. The medium can be subjected to directional differentiation culture by taking human retinal pigment epithelial cells as raw materials to obtain dopaminergic neuron-like cells capable of generating dopamine.

The present invention provides an agent for treating ophthalmic diseases and a screening method for an agent for treating ophthalmic diseases and the like. The present invention also provides a method for predicting rejection associated with transplantation of retinal pigment epithelial cell to patients with ophthalmic diseases.

The invention relates to the field of cellular biology, in particular to a retinal pigment epithelial cell and a preparation method and application thereof. The retinal pigment epithelial cell expresses MITF and ZO-1. The preparation method of the retinal pigment epithelial cell comprises the following steps of S1: culturing human pluripotent stem cells; S2: differentiating the human pluripotent stem cells obtained in S1 into retinal pigment epithelial precursor cells; S3: differentiating the retinal pigment epithelial precursor cells obtained in S2 into immature retinal pigment epithelial cells; and S4: differentiating the immature retinal pigment epithelial cells obtained in S3 to obtain retinal pigment epithelial cells. The preparation method can differentiate pluripotent stem cells rapidly, efficiently and simply to obtain retinal pigment epithelial cells. In addition, no system containing serum or a serum substitute is used in the preparation method provided by the invention. Thedifferentiation efficiency is high and the differentiation effect is stable. The purification method is simple and the obtained cell has high purity.